Biotech: Page

  • An entrance to a National Institutes of Health building is lit by the sun on a clear day.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trump administration

    Federal judge extends block on Trump plan to limit NIH payouts

    A District Court judge issued a nationwide preliminary injunction against the administration’s plan to cap so-called indirect costs associated with NIH grants — a policy with broad implications for the U.S. drug industry.  

    By Kristin Jensen • March 6, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Amgen readies pivotal MariTide trials; Novo offers discounted Wegovy

    Phase 3 studies for Amgen’s closely watched obesity drug were posted on a federal database. Elsewhere, the FDA cleared for testing a first-of-its-kind base editing therapy for Duchenne.

    By BioPharma Dive staff • March 6, 2025
  • Colorized scanning electron micrograph of a natural killer cell from a human donor. Explore the Trendline➔
    Image attribution tooltip
    National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
    Image attribution tooltip
    Trendline

    Cell therapy

    The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.

    By BioPharma Dive staff
  • A person writes on a check.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Sofinnova secures €1.2B for new biotech investments

    The funding can support investment in as many as 60 new life sciences companies, said Sofinnova chairman Antoine Papiernik.

    By • March 4, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Neumora bids farewell to R&D head; Biohaven’s ‘one step forward, one step back’ data

    Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Atara is cutting half of its staff after shelving two cell therapy programs.

    By BioPharma Dive staff • March 4, 2025
  • An illustration of leukocytes attacking a cancer cell
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Deep Dive // State of Play

    Blocking PD-1 and VEGF: The bispecific cancer drugs that could best Keytruda

    Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of research practically overnight.

    By • March 4, 2025
  • A blood sample of HER2 for breast cancer diagnosis.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Startup launches

    Biotech startup pulls in $187M to make ‘multi-payload’ ADCs

    Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer Hummingbird Bioscience.

    By • March 3, 2025
  • An illustration of the KRAS protein
    Image attribution tooltip
    Retrieved from National Cancer Institute on September 27, 2019
    Image attribution tooltip

    BridgeBio oncology spinout to go public in blank-check merger

    The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased federal oversight.

    By • Feb. 28, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Praxis hits trial setback; Bristol Myers lays off staff in New Jersey

    The brain drug developer is continuing a trial despite a recommendation it be stopped for futility. Elsewhere, Eli Lilly struck a molecular glue deal and Zevra sold a priority review voucher.

    By BioPharma Dive staff • Feb. 28, 2025
  • A sign spelling Vertex hangs over an office building entrance.
    Image attribution tooltip
    Courtesy of Vertex Pharmaceuticals
    Image attribution tooltip
    Gene editing

    Vertex ends gene editing research pact with Verve

    Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited “changing priorities.”

    By Kristin Jensen • Feb. 27, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    AstraZeneca’s next breast cancer drug; Madrigal’s accelerating MASH launch

    The British drugmaker claimed success in a first-line breast cancer study. Elsewhere, Rezdiffra sales continued to grow and a cancer biotech cut staff.

    By BioPharma Dive staff • Feb. 26, 2025
  • A visualization, in green lights, of Eikon's particle tracking platform.
    Image attribution tooltip
    Permission granted by Eikon Therapeutics
    Image attribution tooltip
    Startup launches

    Eikon raises $351M in one of the year’s largest biotech venture rounds

    The funding comes as Eikon, run by former Merck research chief Roger Perlmutter, has started a Phase 3 trial testing one of its cancer drugs.

    By • Feb. 26, 2025
  • An entrance to a National Institutes of Health building is lit by the sun on a clear day.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    ‘Fear and uncertainty’: Biotech investors warn of impact from NIH research cuts

    The Trump administration’s plans to reduce NIH grant funding could have long-term consequences for the U.S. drug industry, investors said.

    By • Feb. 25, 2025
  • artwork symbolizing biotechnology and clinical trials
    Image attribution tooltip
    Permission granted by ICON
    Image attribution tooltip
    Sponsored by ICON

    Partnering for success in early phase clinical development

    Early-phase clinical trials, including phase 1 and some phase 2a studies, serve as a pivotal step for biotech companies, laying the foundation for a drug candidate’s journey to market.

    Feb. 24, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Ozempic, Wegovy shortage resolved; Pfizer CEO is PhRMA’s new chair

    The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a competing bid for Acelyrin and Intra-Cellular sales rose.

    By BioPharma Dive staff • Updated Feb. 24, 2025
  • A Bluebird bio employee works at a laboratory.
    Image attribution tooltip
    Permission granted by Bluebird bio
    Image attribution tooltip

    Bluebird, at risk of default, agrees to take-private deal

    The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of what it was once worth.

    By • Feb. 21, 2025
  • A photo of BridgeBio Pharma CEO Neil Kumar
    Image attribution tooltip
    Permission granted by BridgeBio Pharma
    Image attribution tooltip

    BridgeBio’s heart drug launch gets off to a fast start

    Prescription totals for Attruby, which is locked in a closely watched commercial battle with Pfizer’s tafamidis, have more than doubled since January and outpaced investor expectations.

    By • Feb. 20, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Sanofi reaches consumer health deal; Supernus antidepressant fails study

    The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Ultragenyx secured a PDUFA date for its Sanfilippo gene therapy.

    By BioPharma Dive staff • Feb. 19, 2025
  • A woman works in one of Recursion's labs.
    Image attribution tooltip
    Courtesy of Recursion Pharmaceuticals
    Image attribution tooltip

    Recursion CEO launches pre-seed fund in response to NIH cuts

    Chris Gibson, Recursion’s head, cited the role small business grants played in helping his company grow its business.

    By • Feb. 19, 2025
  • Stock prices are seen on a window reflection.
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip
    Emerging biotech

    ‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public

    The heads of three early-stage companies shared lessons from going public in a challenging market for biotech stocks.

    By • Feb. 14, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Neumora shakes up its C-suite; Biogen cuts early-stage pipeline

    Henry Gosebruch, Neumora’s CEO since 2023, will depart. Elsewhere, Biogen dropped two antisense drugs in a pipeline cull and Voyager hit a setback for its ALS gene therapy.

    By BioPharma Dive staff • Feb. 13, 2025
  • A 3D rendered image of a neural cell network, colored blue and set against a black background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    A brain biotech launches with Roche’s spare parts

    Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and a plan to develop drugs for brain function and health.

    By • Feb. 13, 2025
  • DEI diversity Nasdaq
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip
    IPO window

    Aardvark prices $94M IPO to fund Prader-Willi, obesity drug work

    Proceeds will support testing of drugs designed to suppress hunger in people with the tough-to-treat rare disease and, potentially, more common obesity-related conditions.

    By • Feb. 12, 2025
  • A photo of a Biogen building
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    Biogen inks royalty deal to gain funding for lupus drug R&D

    The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, which is in a pair of late-stage studies in lupus. 

    By Kristin Jensen • Feb. 12, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK

    The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority review on a key drug and Third Harmonic restructured.

    By BioPharma Dive staff • Feb. 11, 2025
  • A sign spelling Vertex hangs over an office building entrance.
    Image attribution tooltip
    Courtesy of Vertex Pharmaceuticals
    Image attribution tooltip

    Vertex COO Arbuckle to step down later this year

    Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex works to build markets for new drugs like Casgevy and Journavx.

    By Ned Pagliarulo • Feb. 10, 2025